GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. GeneDx utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information. The Legacy Sema4 diagnostics segment provides reproductive and women's health and somatic oncology diagnostic testing and screening products.

Employees

1,000

Sector

Healthcare Facilities & Services

Calendar

2024-11-10 - Q3 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
24-09-10	33.67 $	-0.18%	205,543
24-09-09	33.73 $	+2.24%	329,635
24-09-06	32.99 $	+1.13%	231,744
24-09-05	32.62 $	+10.13%	391,741
24-09-04	29.62 $	-3.61%	415,788

Delayed Quote Nasdaq, September 10, 2024 at 04:00 pm EDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

33.67USD

Average target price

40.83USD

Spread / Average Target

+21.28%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2024-09-10 pm EDT			5-day change	1st Jan Change
33.67 ^USD	-0.18%		+9.57%	+1,124.36%

Aug. 28	Wells Fargo Initiates GeneDx Holdings at Equalweight With $34 Price Target	MT
Jul. 30	Transcript : GeneDx Holdings Corp., Q2 2024 Earnings Call, Jul 30, 2024

Capitalization	909M	P/E ratio 2024 *	-12.4x	P/E ratio 2025 *	-57.1x
Enterprise value	-6.28M	EV / Sales 2024 *	3.21x	EV / Sales 2025 *	2.78x
Free-Float	73.37%	Yield 2024 *	-	Yield 2025 *	-

Wells Fargo Initiates GeneDx Holdings at Equalweight With $34 Price Target	Aug. 28	MT
Transcript : GeneDx Holdings Corp., Q2 2024 Earnings Call, Jul 30, 2024	Jul. 30
Earnings Flash (WGS) GENEDX Posts Q2 Revenue $70.5M, vs. Street Est of $59.3M	Jul. 30	MT
GeneDx Holdings Corp. Provides Earnings Guidance for the Year 2025	Jul. 30	CI
GeneDx Holdings Corp. Revises Earnings Guidance for the Year 2024	Jul. 30	CI
GeneDx Holdings Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Jul. 30	CI
GeneDx Announces Whole Genome Sequencing Product Enhancements to Accelerate Diagnoses for More Patients	Jul. 30	CI
Craig-Hallum Initiates Coverage on GeneDx With Buy Rating, $43 Price Target	Jul. 10	MT
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell Small Cap Comp Value Index	Jun. 30	CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell Small Cap Completeness Index	Jun. 30	CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell Microcap Growth Index	Jun. 30	CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell 3000 Value Index	Jun. 30	CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell 2000 Index	Jun. 30	CI

Wells Fargo Initiates GeneDx Holdings at Equalweight With $34 Price Target	Aug. 28	MT
Craig-Hallum Initiates Coverage on GeneDx With Buy Rating, $43 Price Target	Jul. 10	MT
BTIG Adjusts Price Target on GeneDx Holdings to $35 From $19, Maintains Buy Rating	Jun. 26	MT
TD Cowen Adjusts GeneDx Holdings' Price Target to $24 From $14, Keeps Buy Rating	Apr. 30	MT
BTIG Adjusts GeneDx Holdings' Price Target to $19 From $15, Keeps Buy Rating	Apr. 30	MT

GeneDx Holdings Corp. Stock

Equities

WGS

US81663L2007

Healthcare Facilities & Services

Valuation: GeneDx Holdings Corp.

Chart: GeneDx Holdings Corp.

Latest news: GeneDx Holdings Corp.

Last Transcript: GeneDx Holdings Corp.

Analysts' recommendations: GeneDx Holdings Corp.

Press Releases: GeneDx Holdings Corp.

Quotes and Performance

Course Extremes

Managers and Directors: GeneDx Holdings Corp.

ETFs: GeneDx Holdings Corp.

Medical & Diagnostic Laboratories

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly earnings, Rate of surprise

GeneDx to Participate in Fall Investor Conferences	Aug. 12	BU
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	Aug. 12	AQ
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Aug. 09	BU
GeneDx : Q2 2024 Earnings Presentation	Jul. 30	PU
GeneDx Announces Whole Genome Sequencing (WGS) Product Enhancements to Accelerate Diagnoses for More Patients	Jul. 30	BU

1 day	-0.18%
1 week	+5.42%
Current month	+5.42%
1 month	+2.84%
3 months	+34.63%
6 months	+301.31%
Current year	+1,124.36%

Director	Title	Age	Since
Katherine Stueland CEO	Chief Executive Officer	48	22-04-28
Kevin Feeley DFI	Director of Finance/CFO	43	-
Paul Kruszka CTO	Chief Tech/Sci/R&D Officer	-	-

Manager	Title	Age	Since
Joshua Ruch BRD	Director/Board Member	74	21-07-21
Eli Casdin BRD	Director/Board Member	51	20-06-30
Emily Leproust BRD	Director/Board Member	51	20-08-31

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
GENEDX HOLDINGS CORP.	-0.18%	+5.42%	+627.21%	-88.55%	909M
SONIC HEALTHCARE LIMITED	-0.48%	-3.66%	-13.67%	-35.50%	8.61B
RADNET, INC.	-0.84%	-8.98%	+100.20%	+107.64%	4.5B
DR. LAL PATHLABS LIMITED	-0.03%	-0.34%	+52.33%	-17.96%	3.35B
SYNLAB AG	-0.18%	-.--%	+21.67%	-47.23%	2.68B
NEOGENOMICS, INC.	+3.17%	-5.45%	+14.94%	-69.56%	1.94B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-0.40%	+7.17%	-54.07%	-73.30%	1.8B
FLEURY S.A.	+3.26%	+2.11%	+13.98%	-26.75%	1.62B
METROPOLIS HEALTHCARE LIMITED	+0.84%	+2.86%	+52.90%	-27.81%	1.31B
VIJAYA DIAGNOSTIC CENTRE LIMITED	-0.04%	+2.17%	+89.23%	-	1.12B
Average	+0.51%	-0.38%	+90.47%	-31.00%	2.79B
Weighted average by Cap.	+0.11%	-2.20%	+45.25%	-16.30%

	2024 *	2025 *
Net sales	263M	301M
Net income	-77.85M	-26.95M
Net Debt	-63.72M	-72.76M